德国及波兰等欧盟国家称数据不足 不建议老年人接种阿斯利康疫苗
英国药厂阿斯利康(AstraZeneca)与牛津大学共同研发的新冠病毒疫苗,但由於未有足够临床测试数据证明能够对老年人提供足够的保护,故即使在欧盟药品管理局的批准下,德国及波兰等欧盟国家仍不建议老年人接种阿斯利康疫苗。
阿斯利康与牛津大学表示,参与测试的65岁以上人士不到一成,而70岁以上人士仅只有450人。相比之下,辉瑞与BioNTech疫苗的临床测试中,55岁以上人士占超过四成。
欧盟药品管理局表示,虽然缺乏充分数据证明阿斯利康疫苗对老年人有效,但认为疫苗仍会有一定的保护作用,因此按照英国的做法,批准阿斯利康疫苗用於老年人身上。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.